We are live on ! Find out more
LFCR icon

Lifecore Biomedical

111 hedge funds and large institutions have $282M invested in Lifecore Biomedical in 2015 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 40 increasing their positions, 36 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

57% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 7

11% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 36

3% more funds holding

Funds holding: 108111 (+3)

21% less capital invested

Capital invested by funds: $355M → $282M (-$73.6M)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
111
Holders Change
+3
Holders Change %
+2.78%
% of All Funds
3.1%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
11
Increased
40
Reduced
36
Closed
7
Calls
$147K
Puts
Net Calls
+$147K
Net Calls Change
+$140K

LFCR Hedge Fund Activity: Q3 2015 in Review

111 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q3 2015, worth a combined $282M — down 21% from $355M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new LFCR positions and 7 closed out — a net gain of 4 holders — while 40 added to existing stakes and 36 trimmed.

The largest buyer was Boston Partners, adding an estimated $2.87M. The largest seller was Guggenheim Capital, cutting an estimated $5.79M.

  • 111 institutional investors held Lifecore Biomedical (LFCR) as of Q3 2015, up from 108 in Q2 2015.
  • Funds reported $282M of Lifecore Biomedical stock for Q3 2015, down 21% quarter-over-quarter.
  • 11 funds opened new Lifecore Biomedical positions in Q3 2015 and 7 closed out, a net change of +4 holders.
  • The largest Lifecore Biomedical buyer in Q3 2015 was Boston Partners, an estimated $2.87M added.
  • The largest Lifecore Biomedical seller in Q3 2015 was Guggenheim Capital, an estimated $5.79M sold.

Based on aggregated 13F filings for Q3 2015.